SCHEDULE: RA Capital Amends VOR Biopharma Stake to 19.9%

RA Capital Management, L.P. and its affiliates filed an Amendment No. 13 to their Schedule 13D, reporting a beneficial ownership of 19.9% in VOR Biopharma Inc. due to an increase in outstanding shares.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (Reporting Persons) filed Amendment No. 13 to their Schedule 13D.
• The amendment reports an increase in the number of VOR Biopharma Inc. common shares deemed beneficially owned by the Reporting Persons.
• This increase is a result of an increase in the Issuer's outstanding shares, not from new acquisitions or dispositions by the Reporting Persons.
• The Reporting Persons collectively beneficially own 12,187,524 shares of VOR Biopharma Inc. common stock.
• This represents 19.9% of the Issuer's common stock, based on 54,185,582 shares outstanding as of March 30, 2026.
• Beneficial ownership includes 5,404,998 shares directly held by the Fund, Common Stock Warrants for up to 1,056,072 shares, Pre-Funded Warrants for up to 10,000,000 shares, and stock options for 6,190 shares (Joshua Resnick) and 416 shares (Andrew Levin).
• Warrants are subject to beneficial ownership blockers (9.99% for common stock warrants, 19.99% for pre-funded warrants) preventing full exercise if it exceeds these thresholds.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive update, as a major institutional investor is maintaining a significant stake, indicating continued confidence, despite warrant exercise limitations.

Positives

• RA Capital maintains a significant stake (19.9%) in VOR Biopharma, indicating continued institutional interest.
• The increase in beneficial ownership percentage is due to an increase in the Issuer's outstanding shares, not a reduction in RA Capital's holdings.

Negatives

• Warrant exercise is currently restricted by beneficial ownership blockers, limiting immediate upside from full exercise.

Risks

• The value of the beneficial ownership is subject to the market performance of VOR Biopharma Inc.'s common stock.
• Warrant exercise is constrained by beneficial ownership blockers, which could limit the Reporting Persons' ability to increase their stake beyond current thresholds without further regulatory considerations or changes.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding VOR Biopharma Inc.'s operational or financial performance, beyond the future vesting of certain stock options.

Industry Context

StockSavvy.ai notes that Schedule 13D filings, particularly amendments, are standard regulatory disclosures for significant institutional investors. RA Capital Management's continued substantial stake in VOR Biopharma Inc. reflects ongoing institutional confidence in the biopharma sector, especially in companies like VOR that may be in development stages. The maintenance of a 19.9% stake, even with an increase in the issuer's outstanding shares, suggests a stable long-term investment perspective from a prominent healthcare-focused fund.

Stakeholder Impact

• Shareholders: Provides transparency regarding a major institutional investor's stake, potentially signaling confidence. The increase in outstanding shares dilutes existing shareholders, but RA Capital's percentage remains high.
• Employees: The mention of stock options for Joshua Resnick and Andrew Levin indicates ongoing equity incentives for key personnel.

Next Steps

• Continued monitoring of VOR Biopharma Inc.'s outstanding shares and RA Capital's beneficial ownership.
• Future vesting of stock options for Andrew Levin within 60 days of the filing date.

Key Dates

Recommendation

The filing is a routine regulatory update (Schedule 13D/A) indicating that a significant institutional investor, RA Capital, maintains a substantial 19.9% stake in VOR Biopharma. The change in reported percentage is due to an increase in the issuer's outstanding shares, not a new acquisition or disposition by RA Capital. While the continued large stake suggests ongoing institutional confidence, the filing itself does not contain new information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further fundamental updates from VOR Biopharma.

Keywords

VOR Biopharma, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Institutional Investor, Biopharma, Warrants, Stock Options, SEC Filing, Equity Stake